<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00887432</url>
  </required_header>
  <id_info>
    <org_study_id>I 128308</org_study_id>
    <secondary_id>NCI-2009-01530</secondary_id>
    <secondary_id>I 128308</secondary_id>
    <secondary_id>P30CA016056</secondary_id>
    <nct_id>NCT00887432</nct_id>
  </id_info>
  <brief_title>Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation</brief_title>
  <official_title>Randomized Placebo-Controlled, Double-Blind Study of Cholecalciferol Replacement in Patients on Expectant Management for Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized clinical trial studies how well cholecalciferol supplement works in treating&#xD;
      patients with localized prostate cancer undergoing observation. Cholecalciferol may help&#xD;
      prostate cancer cells become more like normal cells, and to grow and spread more slowly.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the prostate-specific antigen (PSA) response with oral high dose vitamin D3&#xD;
      supplementation (cholecalciferol) in patients with localized, histologically proven&#xD;
      adenocarcinoma of the prostate who have not received any treatment for prostate cancer ever&#xD;
      and have chosen expectant management.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To examine the pattern of response of PSA dynamics as well as the absolute change in PSA&#xD;
      following vitamin D3 supplementation.&#xD;
&#xD;
      II. Assess the toxicity of vitamin D3 supplementation in men with prostate cancer.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. Track occurrence of infections, deep venous thrombosis, vascular events and falls in the&#xD;
      study population.&#xD;
&#xD;
      II. To evaluate relationship between cytochrome P450 family 24 (CYP24), 27B1,&#xD;
      single-nucleotide polymorphism (SNPs) and serum 25(hydroxy [OH]) vitamin D response to oral&#xD;
      D3 supplementation.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Patients receive cholecalciferol orally (PO) once daily (QD) for 9 months in the&#xD;
      absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months,&#xD;
      patients cross-over to Arm II.&#xD;
&#xD;
      ARM II: Patients receive placebo PO QD for 9 months in the absence of disease progression or&#xD;
      unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to Arm I.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 8, 2009</start_date>
  <completion_date type="Actual">June 8, 2020</completion_date>
  <primary_completion_date type="Actual">June 8, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA Response</measure>
    <time_frame>9 month period: pre-Vitamin D/pre-placebo to 9 months after start of vitamin D/ placebo, up to 30 days after completion of study treatment</time_frame>
    <description>Difference in the mean change in PSA on vitamin D (9 month period: pre-Vitamin D to 9 months after start of vitamin D) versus on placebo (9 month period: pre-Placebo to 9 months after starting placebo).&#xD;
Compared using a paired t-test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Slope of PSA Concentration Over Time</measure>
    <time_frame>9 month period: pre-Vitamin D/pre-placebo to 9 months after start of vitamin D/ placebo, up to 30 days after completion of study treatment -Up to 30 days after completion of study treatment</time_frame>
    <description>The PSA levels were modeled as a function of treatment, time, their interaction, sequence, and a random subject effect using a linear mixed model. From this model, the subject specific PSA slope was obtained for each subject under each condition (vitamin D versus placebo). The PSA slopes were then compared between treatment conditions using linear mixed model to account for treatment arm and repeated measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0</measure>
    <time_frame>Up to 30 days after completion of study treatment (up to 22 months from start of study).</time_frame>
    <description>Summarizing the maximum observed treatment related adverse event. Summarize by arm and grade using frequencies and relative frequencies..</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (cholecalciferol and placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cholecalciferol PO QD for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to Arm II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo and cholecalciferol)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive placebo PO QD for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to Arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (cholecalciferol and placebo)</arm_group_label>
    <arm_group_label>Arm II (placebo and cholecalciferol)</arm_group_label>
    <other_name>9,10-Secocholesta-5,7,10(19)-trien-3-ol</other_name>
    <other_name>Calciol</other_name>
    <other_name>Delsterol</other_name>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (cholecalciferol and placebo)</arm_group_label>
    <arm_group_label>Arm II (placebo and cholecalciferol)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient Observation</intervention_name>
    <arm_group_label>Arm I (cholecalciferol and placebo)</arm_group_label>
    <arm_group_label>Arm II (placebo and cholecalciferol)</arm_group_label>
    <other_name>Active Surveillance</other_name>
    <other_name>deferred therapy</other_name>
    <other_name>expectant management</other_name>
    <other_name>Observation</other_name>
    <other_name>Watchful Waiting</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Administration</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (cholecalciferol and placebo)</arm_group_label>
    <arm_group_label>Arm II (placebo and cholecalciferol)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (cholecalciferol and placebo)</arm_group_label>
    <arm_group_label>Arm II (placebo and cholecalciferol)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (cholecalciferol and placebo)</arm_group_label>
    <arm_group_label>Arm II (placebo and cholecalciferol)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient with clinically localized, histologically proven adenocarcinoma of&#xD;
             prostate who has not received any treatment for prostate cancer ever and has chosen&#xD;
             active surveillance; treatment for prostate cancer is defined as prostatectomy,&#xD;
             androgen deprivation, brachytherapy or a full course of external beam irradiation&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Willingness to comply with study guidelines&#xD;
&#xD;
          -  Willingness and ability to consent&#xD;
&#xD;
          -  25(OH) D3 level less than 40 ng/ml within 3 months of initiation of study; most recent&#xD;
             25 hydroxy D level within last 3 month would be used&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of malabsorption syndrome e.g., pancreatic insufficiency, celiac disease,&#xD;
             tropical sprue&#xD;
&#xD;
          -  Creatinine &gt; 2.0 mg/dL&#xD;
&#xD;
          -  Corrected serum calcium level of &gt; 10.5 mg/dL (serum corrected calcium = serum calcium&#xD;
             + 0.8[4-serum albumin])&#xD;
&#xD;
          -  Most recent PSA value more than 18 months ago&#xD;
&#xD;
          -  Prior or current therapy for prostate cancer&#xD;
&#xD;
          -  Documented history of nephrolithiasis within the past 5 years&#xD;
&#xD;
          -  Patients receiving finasteride (Proscar) or dutasteride (Avodart) or men who have&#xD;
             received either agent within 90 days of entry are ineligible&#xD;
&#xD;
          -  Patients cannot take any additional vitamin D supplementation during study treatment;&#xD;
             patients taking &gt; 2000 IU per day prior to treatment will be ineligible&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Mohler</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 23, 2009</study_first_submitted>
  <study_first_submitted_qc>April 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2009</study_first_posted>
  <results_first_submitted>May 25, 2021</results_first_submitted>
  <results_first_submitted_qc>July 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 10, 2021</results_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT00887432/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cholecalciferol to Placebo</title>
          <description>Patients receive cholecalciferol PO QD for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to placebo PO QD for 9 months.&#xD;
Cholecalciferol: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Patient Observation&#xD;
Placebo Administration: Given PO&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
        </group>
        <group group_id="P2">
          <title>Placebo to Cholecalciferol</title>
          <description>Patients receive placebo PO QD for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to Cholecalciferol PO QD for 9 months.&#xD;
Cholecalciferol: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Patient Observation&#xD;
Placebo Administration: Given PO&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Start Excluded Therapy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not complete treatment</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No reason provided</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Cholecalciferol and Placebo)</title>
          <description>Patients receive cholecalciferol PO QD for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to placebo PO QD for 9 months.&#xD;
Cholecalciferol: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Patient Observation&#xD;
Placebo Administration: Given PO&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Placebo and Cholecalciferol)</title>
          <description>Patients receive placebo PO QD for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to cholecalciferol PO QD for 9 months.&#xD;
Cholecalciferol: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Patient Observation&#xD;
Placebo Administration: Given PO&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="74"/>
            <count group_id="B3" value="132"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="58"/>
                    <count group_id="B2" value="74"/>
                    <count group_id="B3" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="58"/>
                    <count group_id="B2" value="74"/>
                    <count group_id="B3" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" spread="7.0"/>
                    <measurement group_id="B2" value="64.9" spread="6.5"/>
                    <measurement group_id="B3" value="64.3" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="58"/>
                    <count group_id="B2" value="74"/>
                    <count group_id="B3" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="58"/>
                    <count group_id="B2" value="74"/>
                    <count group_id="B3" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="58"/>
                    <count group_id="B2" value="74"/>
                    <count group_id="B3" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum 25(OH)D3</title>
          <description>Baseline vitamin D measured in serum blood samples.</description>
          <population>Lab values were not recorded for all patients.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.1" spread="10.7"/>
                    <measurement group_id="B2" value="30.4" spread="9.0"/>
                    <measurement group_id="B3" value="27.9" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostate Specific Antigen (PSA)</title>
          <population>The PSA at enrollment was not available for all subejcts.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="57"/>
                    <count group_id="B2" value="72"/>
                    <count group_id="B3" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.2" spread="2.9"/>
                    <measurement group_id="B2" value="4.8" spread="2.6"/>
                    <measurement group_id="B3" value="5.0" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PSA Response</title>
        <description>Difference in the mean change in PSA on vitamin D (9 month period: pre-Vitamin D to 9 months after start of vitamin D) versus on placebo (9 month period: pre-Placebo to 9 months after starting placebo).&#xD;
Compared using a paired t-test.</description>
        <time_frame>9 month period: pre-Vitamin D/pre-placebo to 9 months after start of vitamin D/ placebo, up to 30 days after completion of study treatment</time_frame>
        <population>Patients who completed both periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Cholecalciferol</title>
            <description>Patients receive cholecalciferol PO QD for 9 months in the absence of disease progression or unacceptable toxicity.&#xD;
Cholecalciferol: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Patient Observation&#xD;
Placebo Administration: Given PO&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive placebo PO QD for 9 months in the absence of disease progression or unacceptable toxicity.&#xD;
Cholecalciferol: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Patient Observation&#xD;
Placebo Administration: Given PO&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>PSA Response</title>
          <description>Difference in the mean change in PSA on vitamin D (9 month period: pre-Vitamin D to 9 months after start of vitamin D) versus on placebo (9 month period: pre-Placebo to 9 months after starting placebo).&#xD;
Compared using a paired t-test.</description>
          <population>Patients who completed both periods.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="2.13"/>
                    <measurement group_id="O2" value="0.31" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Evaluated the change in PSA under the vitamin D and placebo conditions using the combined data (n=87).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.431</p_value>
            <p_value_desc>Significance level of 0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Paired t-test, df=86</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.36</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Slope of PSA Concentration Over Time</title>
        <description>The PSA levels were modeled as a function of treatment, time, their interaction, sequence, and a random subject effect using a linear mixed model. From this model, the subject specific PSA slope was obtained for each subject under each condition (vitamin D versus placebo). The PSA slopes were then compared between treatment conditions using linear mixed model to account for treatment arm and repeated measures.</description>
        <time_frame>9 month period: pre-Vitamin D/pre-placebo to 9 months after start of vitamin D/ placebo, up to 30 days after completion of study treatment -Up to 30 days after completion of study treatment</time_frame>
        <population>Including evaluable patients, those patients with data available under both the vitamin D and placebo conditions.</population>
        <group_list>
          <group group_id="O1">
            <title>Cholecalciferol</title>
            <description>Patients receive cholecalciferol PO QD for 9 months in the absence of disease progression or unacceptable toxicity.&#xD;
Cholecalciferol: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Patient Observation&#xD;
Placebo Administration: Given PO&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive placebo PO QD for 9 months in the absence of disease progression or unacceptable toxicity.&#xD;
Cholecalciferol: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Patient Observation&#xD;
Placebo Administration: Given PO&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Slope of PSA Concentration Over Time</title>
          <description>The PSA levels were modeled as a function of treatment, time, their interaction, sequence, and a random subject effect using a linear mixed model. From this model, the subject specific PSA slope was obtained for each subject under each condition (vitamin D versus placebo). The PSA slopes were then compared between treatment conditions using linear mixed model to account for treatment arm and repeated measures.</description>
          <population>Including evaluable patients, those patients with data available under both the vitamin D and placebo conditions.</population>
          <units>(ng/mL) / day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000434" spread="0.000089"/>
                    <measurement group_id="O2" value="0.000245" spread="0.000090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Comparing the mean PSA slopes between conditions (on vitamin D versus on placebo).</non_inferiority_desc>
            <p_value>0.112</p_value>
            <p_value_desc>Significance level of 0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.00019</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00042</ci_lower_limit>
            <ci_upper_limit>0.000045</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0</title>
        <description>Summarizing the maximum observed treatment related adverse event. Summarize by arm and grade using frequencies and relative frequencies..</description>
        <time_frame>Up to 30 days after completion of study treatment (up to 22 months from start of study).</time_frame>
        <population>All patients receiving any treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Cholecalciferol</title>
            <description>Patients receive cholecalciferol PO QD for 9 months in the absence of disease progression or unacceptable toxicity.&#xD;
Cholecalciferol: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Patient Observation&#xD;
Placebo Administration: Given PO&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive placebo PO QD for 9 months in the absence of disease progression or unacceptable toxicity.&#xD;
Cholecalciferol: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Patient Observation&#xD;
Placebo Administration: Given PO&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0</title>
          <description>Summarizing the maximum observed treatment related adverse event. Summarize by arm and grade using frequencies and relative frequencies..</description>
          <population>All patients receiving any treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No AE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 5</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Within 30 days of treatment completion (up to 22 months from start of study).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cholecalciferol</title>
          <description>Patients receive cholecalciferol PO QD for 9 months in the absence of disease progression or unacceptable toxicity.&#xD;
Cholecalciferol: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Patient Observation&#xD;
Placebo Administration: Given PO&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients receive placebo PO QD for 9 months in the absence of disease progression or unacceptable toxicity.&#xD;
Cholecalciferol: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Patient Observation&#xD;
Placebo Administration: Given PO&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kris Attwood</name_or_title>
      <organization>Roswell Park Comprehensive Cancer Center</organization>
      <phone>716-845-1300</phone>
      <email>Kris.Attwood@roswellpark.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

